![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FATE OF VON ESCHENBACH'S NOMINATION UNCERTAIN
FATE OF VON ESCHENBACH'S NOMINATION UNCERTAIN
The Bush administrations nomination of Andrew von Eschenbach to be the FDA commissioner faces an uncertain future that has less to do with the new Democratic Senate leadership than it does with members of the presidents own party.
Although the nomination passed out of committee Sept. 20, Sens. Jim DeMint (R-S.C.) and David Vitter (R-La.) have placed holds on von Eschenbachs recommendation. Vitters hold, which he placed because he wants the FDA to allow drug importation, remains despite the fact that Congress passed a limited importation measure, a spokesman said. When DeMint announced his hold, he called on the agency to suspend sales of the contraceptive RU-486, pending an investigation into safety concerns. His office did not respond to a request for comment on whether he is still blocking the nomination.
While a spokesman for Senate Health, Education, Labor and Pensions (HELP) Committee Chairman Mike Enzi (R-Wyo.) said filling the FDA commissioner position permanently was a priority, he could not predict the nominations future. A spokesman for Sen. Edward Kennedy (D-Mass.), who will likely be the HELP chairman when Democrats take control in January, agreed.
Enzi would like to see the matter resolved as quickly as possible, the spokesman said, but he did not know if Senate Majority Leader Bill Frist (R-Tenn.) would allow time for it in the upcoming lame duck session of Congress. A spokesman for Frist said it was too early to plan the sessions agenda.
If the nomination is not handled before the Senate adjourns for the year, Enzis spokesman estimated that von Eschenbach would start at about even odds in Congress under Democratic control.
More trouble for the nomination
may lie with frequent agency critic Sen. Chuck Grassley (R-Iowa), who will lose
his seat as chairman of the Senate Finance Committee but remain the panels
top Republican. Grassley is concerned about von Eschenbachs ability to reform
the agency and worries that he might be too cozy with the drug industry,
the spokesman said.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
18Jul
-
21Oct